A new study published in JAMA Oncology finds that tumor-infiltrating clonal hematopoiesis (TI-CH) is associated with worse overall survival among patients with solid tumors, particularly for those with specific genetic variants.
A recent study published online May 7 in JAMA Oncology has revealed that tumor-infiltrating clonal hematopoiesis (TI-CH) is linked to poorer survival outcomes among individuals diagnosed with solid tumors. The research was conducted by Dabin Yun and colleagues from Chungbuk National University in South Korea, who analyzed whole-genome sequencing data of a large cohort of patients.
The prevalence of TI-CH was measured as the primary outcome, defined by somatic variants in 74 driver genes found in tumor tissue. The study identified that TI-CH was present in 1,943 out of 10,571 patients with solid tumors (18.38%), with a particularly high frequency observed among those carrying TET2 variants and endometrial cancer patients.
The researchers also TI-CH was more common in older age groups and individuals who had received cytotoxic chemotherapy treatments. The study found significant associations between TI-CH and worse overall survival, especially for breast cancer patients. Specifically, the hazard ratios indicated a 1.95-fold increase in risk of death among those with TI-CH compared to those without.
The analysis further revealed that GATA2 variants were significantly associated with poorer pan-cancer overall survival, while TET2 variants specifically correlated with worse breast cancer outcomes. These findings underscore the potential clinical utility of TI-CH as a prognostic biomarker in patients with solid tumors.
"This study highlights the importance of identifying and monitoring TI-CH in oncology practice," the authors conclude. "Further research is needed to validate these findings and explore potential therapeutic interventions targeting TI-CH."
Publication details: Dabin Yun et al, Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors, JAMA Oncology (2026). DOI: 10.1001/jamaoncol.2026.1036
Key medical concepts: Clonal Hematopoiesis Solid Neoplasm Clinical categories Oncology
Who's behind this story? Robert Egan, Bachelor's in mathematical biology and Master's in creative writing, brings unique perspectives on science and language to the editorial team.
